Skip to main content
. 2021 Jan 1;11(5):2364–2380. doi: 10.7150/thno.47996

Figure 3.

Figure 3

Human BMSC-derived sEVs facilitate the drug resistance of MM cells to bortezomib. (A) MM1S, (B) RPMI 8226, (C) U266, or (D) H929 cells were cultured with or without 100 μg/mL BMSC-derived sEVs in the absence or presence of bortezomib (7.5 nM for MM1S, RPMI 8226, and U266 cells, 30 nM for H929 cells) for 48 h and cell viability was measured. One representative result in triplicate of three experiments was presented by histograms. Similar results were obtained in three independent experiments. Student's t-test was used for comparing two groups. (E) MM1S, (F) RPMI 8226, (G) U266, or (H) H929 cells were treated with or without 100 μg/mL BMSC-derived sEVs in the absence or presence of bortezomib for 48 h. Apoptotic cells were determined using 7-AAD and Annexin-V staining and flow cytometry. The proportions of live, early apoptotic or late apoptotic and dead cells were analyzed and presented by histograms. One-way ANOVA followed by multiple compressions was used for comparing multiple groups. Error bar, mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.